Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 4/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7437493 | 0.85 | KMT2A (0.73) | MEN1KMT2AHPGDALDH1A1CHRM2 | |
| SCHEMBL11014192 | 0.83 | MEN1 (0.71) | MEN1KMT2AATMALDH1A1LMNA | |
| SCHEMBL843371 | 0.82 | CHRM2 (0.69) | MEN1KMT2AATMALDH1A1CHRM2 | |
| SCHEMBL16523593 | 0.82 | KMT2A (0.70) | MEN1KMT2AATMALDH1A1CHRM2 | |
| SCHEMBL31547203 | 0.82 | MEN1 (0.70) | MEN1KMT2AATMHPGDALDH1A1 | |
| SCHEMBL16523598 | 0.82 | KMT2A (0.70) | MEN1KMT2AATMALDH1A1LMNA | |
| SCHEMBL12976485 | 0.82 | KMT2A (0.70) | MEN1KMT2AATMALDH1A1LMNA | |
| SCHEMBL22305089 | 0.81 | KMT2A (0.68) | MEN1KMT2AATMALDH1A1CHRM2 | |
| Methane SCHEMBL28948442 | 0.80 | CHRM2 (0.67) | MEN1KMT2AATMALDH1A1CHRM2 | |
| SCHEMBL10078178 | 0.78 | MEN1 (0.64) | MEN1KMT2AATMHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1239472-C | HIV integrase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2006-02-01 | — | — | CN | disclosed |
| US-20050043370-A1 | HIV integrase inhibitors | WALKER MICHAEL A (US) | 2005-02-24 | — | — | US | disclosed |
| US-6803378-B2 | FOR THERAPY AND PROPHYLAXIS OF ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS), OR ARC | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-12 | — | — | US | disclosed |
| US-20030181490-A1 | HIV integrase inhibitors | WALKER MICHAEL A (US) | 2003-09-25 | — | — | US | disclosed |
| CN-1441775-A | HIV integrase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2003-09-10 | — | — | CN | disclosed |
| EP-1322599-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20030027847-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-06 | — | — | US | disclosed |
| WO-2001096283-A9 | HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2001096283-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043370-A1 | HIV integrase inhibitors | AKR1C3, CBR3, CBR1 | MEN1 4741/4885KMT2A 1208/4885ATM 2848/4885 |
| US-20030181490-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | MEN1 4837/4885KMT2A 1330/4885ATM 3183/4885 |
| US-20030027847-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | MEN1 4837/4885KMT2A 1330/4885ATM 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.